• MJHLS Brand Logo

© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.

Opportunities for Biosimilars: A Multidisciplinary Perspective

Experts discuss the transition from biologics to biosimilars and emphasize the importance of adaptability when non-medical switching occurs.

EP. 1: Utilizing Recently Approved Biosimilars in Clinical Practice

October 24th 2023

Experts explore current and future use of biosimilars in dermatology, gastroenterology, and rheumatology.

EP. 2: Transitioning to Biosimilars: Considerations for Providers and Payers

October 24th 2023

Panelists explore opportunities for biosimilars to manage inflammatory conditions.

EP. 3: Navigating Challenges Associated with Biosimilars Across Various Disease States

October 31st 2023

Clinical and social challenges associated with biosimilars are discussed by key opinion leaders.

EP. 4: Provider Acceptance Driving Confidence in Biosimilar Therapy

October 31st 2023

Providers speak to the importance of being knowledgeable of efficacy and safety data before prescribing biosimilars to patients.

EP. 5: Decision-Making Process Surrounding Biosimilar Implementation

November 7th 2023

Experts compare approaches to prescribing biosimilars over reference drugs.

EP. 6: Biosimilar Administration Considerations Impacting Patient Experience

November 7th 2023

Panelists discuss reference biologic and biosimilar concentrations as well as the importance of citrate-free, less frequent injectable medications.

EP. 7: Initiating Biosimilar Treatment in Patients Without Previous Reference Biologic Experience

November 14th 2023

Vibeke Strand, MD, evaluates implementation of biosimilars in patients with no history of reference biologic use.

EP. 8: Switching Patients from Reference Product to Biosimilar

November 14th 2023

Insight surrounding the switch from reference drugs to biosimilars is provided by Bincy Abraham, MD, MS.

EP. 9: Defining Interchangeability and Switching in Biologics

November 21st 2023

Medical experts discuss interchangeability designation requirements for biosimilars.

EP. 10: Evolution of Auto-Substitution in Biosimilar Landscape

November 21st 2023

Professionals speak to auto-substitution and its Impact on the shared decision-making process associated with biosimilars.